References
- Cystic Fibrosis (3rd Edition). Hodson ME, Geddes D, Bush A (Eds). Hodder Arnold, London, UK (2007).
- Cystic Fibrosis Foundation Patient Registry 2009. Annual Data Report. Bethesda, MD, USA. Cystic Fibrosis Foundation (2010).
- Döring G, Gulbins E. Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. Cell Microbiol. 11, 208–216 (2009).
- Döring G, Hoiby N; for the Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J. Cyst. Fibros. 3, 67–91 (2004).
- Hoiby N, Frederiksen B. Microbiology of cystic fibrosis. In: Cystic Fibrosis. Hodson ME, Geddes D (Eds). Hodder Arnold, London, UK, 83–108 (2000).
- Tunney MM, Field TR, Moriarty TF et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 177, 995–1001 (2008).
- Ulrich M, Beer I, Braitmaier P et al. Relative contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung pathology in airways of patients with cystic fibrosis. Thorax 65(11), 978–984 (2010).
- Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation by early treatment. Lancet 338, 725–726 (1991)
- Döring G. Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients. Intern. J. Med. Microbiol. 300, 573–577 (2010).
- Döring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26, 1011–1024 (2008).
- Zuercher AW, Horn MP, Que JU et al. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol. Med. Microbiol. 47, 302–308 (2006).
- Döring G, Meisner C, Stern M; for the Flagella Vaccine Trial Study Group. A double-blind randomized placebo-controlled Phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl Acad. Sci. USA 104, 11020–11025 (2007).
- Crowe BA, Enzensberger O, Schober-Bendixen S et al. The first clinical trial of Immuno's experimental Pseudomonas aeruginosa flagellar vaccines. Antibiot. Chemother. 44, 143–146 (1991).
- Döring G, Pfeiffer C, Weber U, Mohr-Pennert A, Dorner F. Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals. Am. J. Respir. Crit. Care Med. 151, 983–985 (1995).
- Taccetti G, Campana S, Festini F, Mascherini M, Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur. Respir. J. 26, 1–4 (2005).
- Nilsson E, Larsson A, Olesen HV, Wejåker PE, Kollberg H. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr. Pulmonol. 43, 892–899 (2008).
- Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. The Cochrane Library, Issue 7 (2011).
- Rhorer J, Ambrose CS, Dickinson S et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 27, 1101–1110 (2009).